Critical mass generally refers to lesions between benign and malignant tumors, with the possibility of infiltration and malignancy, and generally do not need to take Shiroda after undergoing total excision surgery. Shiroda, also known as capecitabine, is an antitumor drug that is converted to 5-fluorouracil under the action of enzymes, which can inhibit the division of tumor cells and affect protein synthesis, thus exerting antitumor effects. It can be used in combination chemotherapy for breast cancer or single-agent chemotherapy for breast cancer. Chemotherapy is generally not needed after total excision of critical breast mass, but one should be alert to the possibility of recurrence or malignant transformation. Pathological examination of the mass after the operation will clarify the nature again, and treatment will be carried out under the doctor’s advice, in addition, it is suggested that the patient should have regular rechecks.